Abiraterone Acetate Withdrawal Syndrome: Does It Exist?
In 2011 abiraterone acetate (AA) was approved for the treatment of castrate-resistant metastatic prostate cancer patients who have failed docetaxel chemotherapy. We report the case of a patient who experienced a confirmed PSA decrease of ≤50% after stopping AA, mimicking an antiandrogen withdrawal s...
| Main Authors: | , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
S. Karger AG
2012
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3409514/ |